title: A novel series of 2,6,7-substituted 2,3-dihydro-1,4-benzodioxin and 2,6,7-substituted 1,4-benzodioxin derivatives as lipid peroxidation inhibitors. Structure-activity relationships for high inhibition of human low-density lipoprotein peroxidation.
abstract: A series of 6- or 7-substituted 2-carboxamido- or 2-(aminomethyl)-1,4-benzodioxin and -2,3-dihydro-1,4-benzodioxin derivatives were synthesized and evaluated to determine the necessary structural requirements for a high inhibition of human low-density lipoprotein copper-induced peroxidation. The most active compounds (21, 25, 28, 36, and 37) were found between 5 and >45 times more active than probucol itself. Due to both their potency and their structural features, compounds 25 and 36 were selected with others for complementary in vitro and in vivo investigations. Both of them exhibit calcium antagonist properties in the same range of potency as flunarizine itself. Compound 36 was also found to have significant hypolipaemic activity in mice at 100 and 300 mg/kg po, while compound 25 proved to be clearly active in a normobar hypoxia test.
authors.affiliation: Institut de Chimie Organique et Analytique, UMR CNRS 6005, Université d'Orléans, B.P. 6759, F-45067 Orléans Cedex 2, France.
authors.forename: V
authors.initials: V
authors.lastname: Thiéry
authors.forename: G
authors.initials: G
authors.lastname: Coudert
authors.forename: J G
authors.initials: JG
authors.lastname: Bizot-Espiard
authors.forename: B
authors.initials: B
authors.lastname: Pfeiffer
authors.forename: P
authors.initials: P
authors.lastname: Renard
authors.forename: A
authors.initials: A
authors.lastname: Lindenbaum
authors.forename: G
authors.initials: G
authors.lastname: Guillaumet
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D001013:Aorta, Thoracic / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D003300:Copper / Q000737:chemistry; D004147:Dioxins / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D004149:Dioxoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects*; D008077:Lipoproteins, LDL / Q000097:blood / Q000737:chemistry; D008079:Lipoproteins, VLDL / Q000097:blood / Q000737:chemistry; D008297:Male; D051379:Mice; D010879:Piperazines / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: C439957:6-hydroxy-2-((4-(bis(4--fluorophenyl)methyl)piperazin-1-yl)methyl)-1,4-benzodioxin; C439956:6-hydroxy-2-((4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)oxo)-1,4-benzodioxin; D000975:Antioxidants; D002121:Calcium Channel Blockers; D004147:Dioxins; D004149:Dioxoles; D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010879:Piperazines; D003300:Copper